The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this series, we hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.
…
continue reading
The Trial Talk Podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this new series, we will hear from world-leading experts about the studies we carry out. We will get inside trials on cancer, infections, and neurodegenerative diseases, explore how public and patient involvement is shaping our studies, and discover new ways to run smarter studies.
…
continue reading

1
Episode 8: International Clinical Trials Methodology Conference 2024 roundup - Early Careers Edition
25:11
25:11
Play later
Play later
Lists
Like
Liked
25:11At the start of October, lots of the Unit’s clinical trials methodology researchers travelled to Edinburgh, for the 7th International Clinical Trials Methodology Conference (ICTMC). ICTMC is the largest academic-led conference on clinical trials, bringing together trialists from across the globe to present their latest work in trials methodology. T…
…
continue reading

1
International Clinical Trials Methodology Conference 2024 roundup - early careers edition
25:09
25:09
Play later
Play later
Lists
Like
Liked
25:09At the start of October, lots of the Unit’s clinical trials methodology researchers travelled to Edinburgh, for the 7th International Clinical Trials Methodology Conference (ICTMC).ICTMC is the largest academic-led conference on clinical trials, bringing together trialists from across the globe to present their latest work in trials methodology. Th…
…
continue reading

1
Episode 7: Preventing multidrug-resistant tuberculosis
32:51
32:51
Play later
Play later
Lists
Like
Liked
32:51In September 2024, the World Health Organization (WHO) released new guidance on preventative treatment for tuberculosis (TB). Thanks to new evidence from two randomised controlled clinical trials, the WHO now recommends that contacts of people with multidrug-resistant TB take six months of daily levofloxacin. In this episode of the Trial Talk podca…
…
continue reading

1
Episode 6: The OPTIC study: Patient views on optimising immunotherapy in cancer
25:24
25:24
Play later
Play later
Lists
Like
Liked
25:24Optimisation immunotherapy clinical trials investigate ways of reducing the intensity of immunotherapy cancer treatment. This could be beneficial for patients’ quality of life. But these trials can be challenging to run, as patients may be concerned about the impact that reducing the intensity of treatment could have on the cancer. This episode of …
…
continue reading

1
Episode 5: Patient and Public Involvement (PPI) in clinical trials
34:44
34:44
Play later
Play later
Lists
Like
Liked
34:44The MRC Clinical Trials Unit at UCL is committed to actively involving patients and the public in our trials. All our Patient and Public Involvement (PPI) work is overseen by our PPI Group, made up of MRC CTU staff alongside seven patient representatives, with a wide range of experience in different areas. In this episode of the Trial Talk podcast,…
…
continue reading

1
Episode 4: Estimands - Answering the right research questions
21:30
21:30
Play later
Play later
Lists
Like
Liked
21:30An estimand is a description of the research question a trial seeks to answer, which can help researchers better understand how their study should be designed and analysed. Estimands also provide a clear way to communicate treatment effects to different stakeholders. This episode of the Trial Talk podcast features Principal Research Fellow Brennan …
…
continue reading

1
Episode 3: Subgroup analysis - Who benefits most from a treatment?
28:45
28:45
Play later
Play later
Lists
Like
Liked
28:45Clinical trial results usually tell us how effective a treatment was on average for the overall group of participants, but a key question for clinicians, patients and policy makers is: which individual patients benefit most from the treatment and which don’t benefit as much? In the latest episode of the Trial Talk podcast, Peter Godolphin and David…
…
continue reading

1
Episode 2: Lessons from UKCTOCS, a large-scale trial in ovarian cancer screening
26:58
26:58
Play later
Play later
Lists
Like
Liked
26:58UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) is one of the largest screening trials in ovarian cancer. More than 200,000 women from England, Wales and Northern Ireland took part in it, and it ran for almost two decades. Designing and running such a large and lengthy trial came with its own challenges. In this episode, Professor Usha…
…
continue reading

1
Lessons from UKCTOCS, a large-scale trial in ovarian cancer screening
26:57
26:57
Play later
Play later
Lists
Like
Liked
26:57UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) is one of the largest screening trials in ovarian cancer. More than 200,000 women from England, Wales and Northern Ireland took part in it, and it ran for almost two decades. Designing and running such a large and lengthy trial came with its own challenges. In this episode, Professor Usha…
…
continue reading

1
Episode 1: Careers in TB trials with Andrew Nunn and Sarah Meredith
28:57
28:57
Play later
Play later
Lists
Like
Liked
28:57In the first episode of our new Trial Talk series, Hanif Esmail and Conor Tweed take over the microphones to interview Andrew Nunn and Sarah Meredith, who have both recently retired from the Unit, having spent a combined total of 92 years working in the field of tuberculosis (TB). As we celebrate Andrew and Sarah’s long and accomplished careers, we…
…
continue reading

1
Careers in TB trials with Andrew Nunn and Sarah Meredith
28:56
28:56
Play later
Play later
Lists
Like
Liked
28:56In the first episode of our new Trial Talk series, Hanif Esmail and Conor Tweed take over the microphones to interview Andrew Nunn and Sarah Meredith, who have both recently retired from the Unit, having spent a combined total of 92 years working in the field of tuberculosis (TB). As we celebrate Andrew and Sarah’s long and accomplished careers, we…
…
continue reading

1
Episode 10 (part 2): World AIDS Day: Bringing hope through research to young people living with HIV with Lungile Jafta and Gugu
19:02
19:02
Play later
Play later
Lists
Like
Liked
19:02Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives. Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the …
…
continue reading

1
Episode 10 (part 1): World AIDS Day: Closing the gap between adults and children with Anna Turkova and Philippa Musoke
24:05
24:05
Play later
Play later
Lists
Like
Liked
24:05Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives. Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the …
…
continue reading

1
World AIDS Day (part 2): Bringing hope through research to young people living with HIV
19:01
19:01
Play later
Play later
Lists
Like
Liked
19:01Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives. Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the …
…
continue reading

1
World AIDS Day (part 1): Closing the gap between adults and children
24:04
24:04
Play later
Play later
Lists
Like
Liked
24:04Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives. Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the …
…
continue reading

1
Episode 9 (part 4): Octopus: Involvement of people affected by MS with Susan Scott
20:03
20:03
Play later
Play later
Lists
Like
Liked
20:03Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recrui…
…
continue reading

1
Octopus (part 4): Involvement of people affected by MS with Susan Scott
20:02
20:02
Play later
Play later
Lists
Like
Liked
20:02Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recrui…
…
continue reading

1
Episode 9 (part 3): Octopus: The patients’ experience with Dawn Lyle and Matthew Justin
24:05
24:05
Play later
Play later
Lists
Like
Liked
24:05Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recrui…
…
continue reading

1
Octopus (part 3): The patients’ experience with Dawn Lyle and Matthew Justin
24:04
24:04
Play later
Play later
Lists
Like
Liked
24:04Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recrui…
…
continue reading

1
Episode 9 (part 2): Octopus: Introducing the trial with Jeremy Chataway
24:11
24:11
Play later
Play later
Lists
Like
Liked
24:11Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL.Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruit…
…
continue reading

1
Octopus (part 2): Introducing the trial with Jeremy Chataway
24:10
24:10
Play later
Play later
Lists
Like
Liked
24:10Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recrui…
…
continue reading

1
Episode 9 (part 1): Octopus: The multiple sclerosis landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin
17:21
17:21
Play later
Play later
Lists
Like
Liked
17:21Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS). Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years. The podcast mini-series …
…
continue reading

1
Octopus (part 1): The MS landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin
17:20
17:20
Play later
Play later
Lists
Like
Liked
17:20Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC CTU at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants…
…
continue reading

1
Optimising treatments with the new MAMS-ROCI design
24:28
24:28
Play later
Play later
Lists
Like
Liked
24:28Innovative platform designs present an opportunity to run faster and more efficient clinical trials. Clinical trials methodology is a research area that looks at how to improve the design, conduct, and analysis of clinical trials. It focuses on developing and implementing new methods to help run trials faster and more efficiently, that will ultimat…
…
continue reading

1
Episode 8: Optimising treatments with the new MAMS-ROCI design
24:29
24:29
Play later
Play later
Lists
Like
Liked
24:29Innovative platform designs present an opportunity to run faster and more efficient clinical trials. Clinical trials methodology is a research area that looks at how to improve the design, conduct, and analysis of clinical trials. It focuses on developing and implementing new methods to help run trials faster and more efficiently, that will ultimat…
…
continue reading

1
Episode 7: STAMPEDE (part 3): Impact and legacy
23:24
23:24
Play later
Play later
Lists
Like
Liked
23:24STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
Episode 7: STAMPEDE (part 2): The role of the patient voice
18:01
18:01
Play later
Play later
Lists
Like
Liked
18:01STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
STAMPEDE (part 3): Impact and legacy with Max Parmar & Nick James
23:23
23:23
Play later
Play later
Lists
Like
Liked
23:23STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
STAMPEDE (part 2): The role of the patient voice with David Matheson, Max Parmar & Nick James
18:00
18:00
Play later
Play later
Lists
Like
Liked
18:00STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
Episode 7: STAMPEDE (part 1): A new era for prostate cancer research
18:04
18:04
Play later
Play later
Lists
Like
Liked
18:04STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
STAMPEDE (part 1): A new era for prostate cancer research with Max Parmar & Nick James
18:03
18:03
Play later
Play later
Lists
Like
Liked
18:03STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the tria…
…
continue reading

1
Episode 6: The REFINE trial: how can we improve the way we give cancer immunotherapy?
16:58
16:58
Play later
Play later
Lists
Like
Liked
16:58Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side…
…
continue reading

1
The REFINE trial: How can we improve the way we give cancer immunotherapy?
16:57
16:57
Play later
Play later
Lists
Like
Liked
16:57Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side…
…
continue reading

1
Episode 5: How can clinical trials make the most of healthcare systems data?
25:40
25:40
Play later
Play later
Lists
Like
Liked
25:40Running a clinical trial means collecting a lot of data from the trial participants. But some of this data might be collected and stored in healthcare systems, as well as in clinical trial case report forms. What if we could avoid this doubling up, save time and resources, improve recruitment and reduce missing data? In this episode we explore the …
…
continue reading

1
How can clinical trials make the most of healthcare systems data?
25:39
25:39
Play later
Play later
Lists
Like
Liked
25:39Running a clinical trial means collecting a lot of data from the trial participants. But some of this data might be collected and stored in healthcare systems, as well as in clinical trial case report forms. What if we could avoid this doubling up, save time and resources, improve recruitment and reduce missing data? In this episode we explore the …
…
continue reading

1
Episode 4: Neonatal infections (part 2): How the NeoSep1 trial will help treat sick newborns
21:14
21:14
Play later
Play later
Lists
Like
Liked
21:14Neonatal sepsis is a life-threatening infection that affects up to 3 million babies per year globally. In an effort to identify better treatments, the NeoSep1 clinical trial evaluates new antibiotic combinations for newborn babies with sepsis. To learn more about the trial, we speak to Adrie Bekker and Cristina Obiero, principal investigators of th…
…
continue reading

1
Neonatal infections (part 2): How the NeoSep1 trial will help treat sick newborns
21:13
21:13
Play later
Play later
Lists
Like
Liked
21:13Neonatal sepsis is a life-threatening infection that affects up to 3 million babies per year globally. In an effort to identify better treatments, the NeoSep1 clinical trial evaluates new antibiotic combinations for newborn babies with sepsis. To learn more about the trial, we speak to Adrie Bekker and Cristina Obiero, principal investigators of th…
…
continue reading

1
Episode 4: Neonatal infections (part 1): The NeoOBS study and the global challenge of neonatal sepsis
23:53
23:53
Play later
Play later
Lists
Like
Liked
23:53214,000 newborn babies die of sepsis caused by infections that are resistant to antibiotics every year. This is a major problem worldwide, but disproportionally affects low- and middle- income countries. Reenu Thomas and Adrie Bekker, two neonatologists from South Africa, and Francesca Schiavone, clinical project manager at the MRC CTU at UCL in Lo…
…
continue reading

1
Neonatal infections (part 1): The NeoOBS study and the global challenge of neonatal sepsis
23:52
23:52
Play later
Play later
Lists
Like
Liked
23:52214,000 newborn babies die of sepsis caused by infections that are resistant to antibiotics every year. This is a major problem worldwide, but disproportionally affects low- and middle- income countries.Reenu Thomas and Adrie Bekker, two neonatologists from South Africa, and Francesca Schiavone, clinical project manager at the MRC CTU at UCL in Lon…
…
continue reading

1
Episode 3: The STREAM2 trial - how should we treat multi-drug resistant tuberculosis?
20:00
20:00
Play later
Play later
Lists
Like
Liked
20:00For World TB Day, this episode explores the global burden of tuberculosis (TB) and how growing antibiotic resistance can complicate treatment options. Andrew Nunn, a Professor of Epidemiology, discusses his work on the STREAM2 trial, which investigated how treatment for multi-drug resistant TB could be shortened and made more acceptable for patient…
…
continue reading

1
The STREAM2 trial: How should we treat multi-drug resistant tuberculosis?
19:59
19:59
Play later
Play later
Lists
Like
Liked
19:59For World TB Day, this episode explores the global burden of tuberculosis (TB) and how growing antibiotic resistance can complicate treatment options. Andrew Nunn, a Professor of Epidemiology, discusses his work on the STREAM2 trial, which investigated how treatment for multi-drug resistant TB could be shortened and made more acceptable for patient…
…
continue reading

1
Episode 2: Part 2 - Sharing the Results of Clinical Trials with Participants
19:51
19:51
Play later
Play later
Lists
Like
Liked
19:51We have an ethical obligation to offer results to trial participants. Annabelle South explores the challenges of sharing results and talks about the best ways of communicating results from an ovarian cancer trial. As a final note, Annabelle reflects on what should be the next steps to ensure that all trial participants find out about the results. T…
…
continue reading

1
Episode 2: Part 1 - Sharing Results of Clinical Trials with Participants
16:02
16:02
Play later
Play later
Lists
Like
Liked
16:02Clinical trials depend on people volunteering to take part, often at increased risk or inconvenience. Research shows that most trial participants want to know what the trial finds, but many never get to find this out. Annabelle South talks about why sharing results is important and how the Show RESPECT study tested different ways of sharing results…
…
continue reading

1
Episode 1: The ARCHERY study – Can AI transform the way we plan radiotherapy treatment globally?
17:26
17:26
Play later
Play later
Lists
Like
Liked
17:26More than 50% of people living with cancer that need radiotherapy in low- and middle-income countries can't have it. Ajay Aggarwal presents the ARCHERY study, an exciting trial looking at the benefits of using artificial intelligence (AI) for radiotherapy treatment planning, which could improve access to high-quality cancer treatment globally. For …
…
continue reading

1
Ovarian cancer screening: The results of the UKCTOCS trial
17:10
17:10
Play later
Play later
Lists
Like
Liked
17:10Around 4000 women die of ovarian cancer in the UK each year. It is often diagnosed at an advanced stage, making treatment difficult. The UK Collaborative Trial of Ovarian Cancer Screening, known as the UKCTOCS trial, followed up more than 200,000 women over an average of 16 years, in an effort to improve diagnosis of ovarian cancer. This podcast ep…
…
continue reading

1
Andrew Nunn talks medical statistics, TB, and Algerian nomads (Part 2)
35:05
35:05
Play later
Play later
Lists
Like
Liked
35:05Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide ad…
…
continue reading

1
Andrew Nunn talks medical statistics, TB, and Algerian nomads (Part 1)
31:40
31:40
Play later
Play later
Lists
Like
Liked
31:40Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide ad…
…
continue reading

1
Jayne Tierney talks systematic reviews, impact, and fish parasites
30:46
30:46
Play later
Play later
Lists
Like
Liked
30:46Jayne Tierney has been a Research Scientist at the Unit since it was formed in 1999, and prior to that, in the Cancer Trials Office in Cambridge. For more than 20 years, she has been responsible for designing and conducting systematic reviews and meta-analyses to rigorously re-evaluate the effectiveness of therapies; projects that have influenced p…
…
continue reading

1
ARREST: Rifampicin for Staph. aureus bacteraemia (full length)
20:20
20:20
Play later
Play later
Lists
Like
Liked
20:20Staphylococcus aureus (S. aureus) bacteraemia is a common infection worldwide, with mortality rates of around 20%, but little research has been done on how best to treat it. This episode explores the results of the ARREST trial, which looked at adding rifampicin to standard antistaphylococcal antibiotic treatment.…
…
continue reading

1
ARREST: Rifampicin for Staph. aureus bacteraemia (short version)
10:10
10:10
Play later
Play later
Lists
Like
Liked
10:10Staphylococcus aureus (S. aureus) bacteraemia is a common infection worldwide, with mortality rates of around 20%, but little research has been done on how best to treat it. This episode explores the results of the ARREST trial, which looked at adding rifampicin to standard antistaphylococcal antibiotic treatment. This is the short version of the r…
…
continue reading